lyophilized powder is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-07-28. Numbers and descriptions here follow the published literature rather than marketing material.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
== Duty of care == In the UK, in April 2008, the Corporate Manslaughter Act was strengthened to target company directors as well as their drivers in cases of road deaths involving vehicles used on business. The Police have said they now treat every road death as 'an unlawful killing' and have the power to seize company records and computers during their investigations. They will bring prosecutions against company directors who fail to provide clear policies and guidance for their employees driving at work. Unfortunately, in the UK a number of businesses are failing to meet their duty of care. In particular prosecutions can be brought against company directors for failing to meet their duty of care and allowing HGV driver hours to exceed the legal limits. Failure to comply with EU rules can result in a fixed penalty of up to £300, a graduated deposit of up to £1500 or you could be summoned to court. Directors and business owners may not be aware that privately owned vehicles used for business journeys are treated exactly the same as company owned vehicles. Directors have an equal responsibility under the law to ensure these vehicles are also roadworthy and correctly insured. It is vital that every company has a 'Driving at Work' policy in place covering every element of their business vehicle operation, no matter how few vehicles are involved and who owns them. Every employee driving for business is required to sign up to the policy. In this way, the directors can reduce the risk of being prosecuted and a possible custodial sentence.
In Asia, two species, in particular, are widely harvested: Korean pine (Pinus koraiensis) in northeast Asia (the most important species in international trade) and chilgoza pine (P. gerardiana) in the western Himalaya. Four other species, Siberian pine (P. sibirica), Siberian dwarf pine (P. pumila), Chinese white pine (P. armandii) and lacebark pine (P. bungeana), are also used to a lesser extent. Russia is the largest producer of P. sibirica nuts in the world, followed by either Mongolia or Afghanistan. They each produce over 10,000 metric tons (9,800 long tons; 11,000 short tons) annually, most of it exported to China. Pine nuts produced in Europe mostly come from the stone pine (P. pinea), which has been cultivated for its nuts for over 5,000 years. Pine nuts have been harvested from wild trees for far longer. The Swiss pine (P. cembra) is also used, to a very small extent. In North America, the main species are three of the pinyon pines: Colorado pinyon (P. edulis), single-leaf pinyon (P. monophylla), and Mexican pinyon (P. cembroides). The other eight pinyon species are used to a small extent, as are gray pine (P. sabineana), Coulter pine (P. coulteri), Torrey pine (P. torreyana), sugar pine (P. lambertiana) and Parry pinyon (P. quadrifolia). Here, the nuts themselves are known by the Spanish name for the pinyon pine, piñón (plural: piñones).
== Pathophysiology == In normal metabolism, the elevated blood glucose level causes beta (β) cells in the Islets of Langerhans, located in the pancreas, to release insulin into the blood. The insulin makes insulin-sensitive tissues in the body (primarily skeletal muscle cells, adipose tissue, and liver) absorb glucose which provides energy as well as lowers blood glucose, in a negative feedback loop. The beta cells reduce insulin output as the blood glucose level falls, allowing blood glucose to settle at a homeostatic constant level of approximately 5 mmol/L (90 mg/dL). In an insulin-resistant individual, normal levels of insulin do not have the same effect in controlling blood glucose levels. When the body produces insulin under conditions of insulin resistance, the cells are unable to absorb or use glucose as effectively and it stays in the bloodstream. Certain cell types such as fat and muscle cells require insulin to absorb glucose and when these cells fail to respond adequately to circulating insulin, blood glucose levels rise. Skeletal muscle is thought to be particularly important in this regard. The liver normally helps regulate glucose levels by reducing its secretion of glucose in the presence of insulin. However, in insulin resistance, this normal reduction in the liver's glucose production may not occur, further contributing to elevated blood glucose. Also, insulin resistance often is associated with a hypercoagulable state (impaired fibrinolysis) and increased inflammatory cytokine levels.
Workers exposed to high air levels of copper (resulting in an estimated intake of 200 mg Cu/d) developed signs suggesting copper toxicity (e.g., elevated serum copper levels, hepatomegaly). However, other co-occurring exposures to pesticidal agents or in mining and smelting may contribute to these effects. Effects of copper inhalation are being thoroughly investigated by an industry-sponsored program on workplace air and worker safety. This multi-year research effort is expected to be finalized in 2011.
== Further reading == All the Birds of the World, Lynx Edicions, 2020. Del Hoyo, Josep; Elliott, Andrew; Sargatal, Jordi (eds.). Handbook of the Birds of the World (17-volume encyclopaedia), Lynx Edicions, Barcelona, 1992–2010. (Vol. 1: Ostrich to Ducks: ISBN 978-84-87334-10-8, etc.). Lederer, Roger; Carol Burr (2014). Latein für Vogelbeobachter: über 3000 ornithologische Begriffe erklärt und erforscht, aus dem Englischen übersetzt von Susanne Kuhlmannn-Krieg, Verlag DuMont, Köln, ISBN 978-3-8321-9491-8. National Geographic Field Guide to Birds of North America, National Geographic, 7th edition, 2017. ISBN 9781426218354 National Audubon Society Field Guide to North American Birds: Eastern Region, National Audubon Society, Knopf. National Audubon Society Field Guide to North American Birds: Western Region, National Audubon Society, Knopf. Svensson, Lars (2010). Birds of Europe, Princeton University Press, second edition. ISBN 9780691143927 Svensson, Lars (2010). Collins Bird Guide: The Most Complete Guide to the Birds of Britain and Europe, Collins, 2nd edition. ISBN 978-0007268146
Sources: en.wikipedia.org
Some corps or units have small variations in their uniforms – for instance, military policemen wear a white belt and police hat. Paratroopers are issued a four pocket tunic (yarkit/yerkit) worn untucked with a pistol belt cinched tight around the waist over the shirt. Most IDF soldiers are issued black leather combat boots, certain units issue reddish-brown leather boots for historical reasons — the paratroopers, combat medics, Nahal and Kfir Brigades, as well as some Special Forces units (Sayeret Matkal, Oketz, Duvdevan, Maglan, and the Counter-Terror School). Women were formerly issued sandals, but this practice has ceased.
==== Chemical reactions in seawater ==== Silver nanoparticles are thermodynamically unstable in oxic environments. In seawater, silver oxide is not thermodynamically favored when chloride and sulfur are present. On the surface where O2 is present in much greater quantities than chloride or sulfur, silver reacts to form a silver oxide surface layer. This oxidation has been shown to occur in nanoparticles as well, despite their shell.Dissolution of Ag2O in Water:Ag2O + H2O → 2Ag− + 2OH− The nano-size of the particles aids in oxidation since their smaller surface area increases their redox potential. The silver oxide layer easily dissolves in water because of its low Ksp value of 4 × 10−11. Possible Oxidation Reactions of Silver:Ag + O2 → Ag+ + O2−4Ag + O2 → 4Ag+ + 2O2−In aerobic, acidic seawater, oxidation of Ag can occur through the following reaction:Oxidation of Silver in Seawater:2Ag(s) + ½ O2(aq) + 2H+(aq) ⇌ 2Ag+(aq) + H2O(l) The formation of these Ag+ ions are a concern for environmental health, as these ions freely interact with other organic compounds, such as humic acids, and disrupt the normal balance of an ecosystem. These Ag+ ions will also react with Cl− to form complexes such as AgCl2−, AgCl32−, and AgCl43−, which are bioavailable forms of silver that are potentially more toxic to bacteria and fish than silver nanoparticles.
In November 2012, 20th Century Fox announced plans to create its own shared universe of Marvel properties it held the rights to, including the Fantastic Four and X-Men, with the hiring of comic book writer Mark Millar as supervising producer. Millar said, "Fox are thinking, 'We're sitting on some really awesome things here. There is another side of the Marvel Universe. Let's try and get some cohesiveness going.' So they brought me in to oversee that really. To meet with the writers and directors to suggest new ways we could take this stuff and new properties that could spin out of it." X-Men: Days of Future Past, released in 2014, was Fox's first step towards expanding their stable of Marvel properties and creating this universe, ahead of the release of a Fantastic Four reboot film the next year. In May 2014, Days of Future Past and Fantastic Four screenwriter Simon Kinberg stated that the latter film would not take place in the same universe as the X-Men films, explaining that "none of the X-Men movies have acknowledged the notion of a sort of superhero team—the Fantastic Four. And the Fantastic Four acquire powers, so for them to live in a world where mutants are prevalent is kind of complicated, because you're like, 'Oh, you're just a mutant.' Like, 'What's so fantastic about you?' ... they live in discrete universes." In July 2015, X-Men director Bryan Singer said that there was still potential for a crossover between the X-Men and Fantastic Four franchises, if reactions to Fantastic Four and X-Men: Apocalypse (2016) warranted it.
Isotope masses from: Audi, Georges; Bersillon, Olivier; Blachot, Jean; Wapstra, Aaldert Hendrik (2003), "The NUBASE evaluation of nuclear and decay properties", Nuclear Physics A, 729: 3–128, Bibcode:2003NuPhA.729....3A, doi:10.1016/j.nuclphysa.2003.11.001 Isotopic compositions and standard atomic masses from: de Laeter, John Robert; Böhlke, John Karl; De Bièvre, Paul; Hidaka, Hiroshi; Peiser, H. Steffen; Rosman, Kevin J. R.; Taylor, Philip D. P. (2003). "Atomic weights of the elements. Review 2000 (IUPAC Technical Report)". Pure and Applied Chemistry. 75 (6): 683–800. doi:10.1351/pac200375060683. Wieser, Michael E. (2006). "Atomic weights of the elements 2005 (IUPAC Technical Report)". Pure and Applied Chemistry. 78 (11): 2051–2066. doi:10.1351/pac200678112051. "News & Notices: Standard Atomic Weights Revised". International Union of Pure and Applied Chemistry. 19 October 2005. Half-life, spin, and isomer data selected from the following sources. Audi, Georges; Bersillon, Olivier; Blachot, Jean; Wapstra, Aaldert Hendrik (2003), "The NUBASE evaluation of nuclear and decay properties", Nuclear Physics A, 729: 3–128, Bibcode:2003NuPhA.729....3A, doi:10.1016/j.nuclphysa.2003.11.001 National Nuclear Data Center. "NuDat 3.0 database". Brookhaven National Laboratory. Holden, Norman E. (2004). "11. Table of the Isotopes". In Lide, David R. (ed.). CRC Handbook of Chemistry and Physics (85th ed.). Boca Raton, Florida: CRC Press. ISBN 978-0-8493-0485-9.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.